tiprankstipranks
Trending News
More News >
Innate Pharma (IPHA)
NASDAQ:IPHA
Advertisement

Innate Pharma (IPHA) Stock Statistics & Valuation Metrics

Compare
119 Followers

Total Valuation

Innate Pharma has a market cap or net worth of $192.93M. The enterprise value is $108.74M.
Market Cap$192.93M
Enterprise Value$108.74M

Share Statistics

Innate Pharma has 92,183,525 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding92,183,525
Owned by Insiders
Owned by Institutions<0.01%

Financial Efficiency

Innate Pharma’s return on equity (ROE) is -5.60 and return on invested capital (ROIC) is -59.43%.
Return on Equity (ROE)-5.60
Return on Assets (ROA)-0.45
Return on Invested Capital (ROIC)-59.43%
Return on Capital Employed (ROCE)-0.66
Revenue Per Employee69.73K
Profits Per Employee-273.32K
Employee Count181
Asset Turnover0.11
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio
PS Ratio0.00
PB Ratio14.38
Price to Fair Value16.30
Price to FCF-19.78
Price to Operating Cash Flow-18.43
PEG Ratio0.06

Income Statement

In the last 12 months, Innate Pharma had revenue of 12.62M and earned -49.47M in profits. Earnings per share was -0.61.
Revenue12.62M
Gross Profit12.62M
Operating Income-51.58M
Pretax Income-49.47M
Net Income-49.47M
EBITDA-46.91M
Earnings Per Share (EPS)-0.61

Cash Flow

In the last 12 months, operating cash flow was -6.90M and capital expenditures -391.00K, giving a free cash flow of -7.29M billion.
Operating Cash Flow-6.90M
Free Cash Flow-7.29M
Free Cash Flow per Share-0.08

Dividends & Yields

Innate Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.29
52-Week Price Change-4.25%
50-Day Moving Average1.96
200-Day Moving Average1.94
Relative Strength Index (RSI)61.07
Average Volume (3m)9.51K

Important Dates

Innate Pharma upcoming earnings date is Sep 17, 2025, Before Open (Confirmed).
Last Earnings DateMar 27, 2025
Next Earnings DateSep 17, 2025
Ex-Dividend Date

Financial Position

Innate Pharma as a current ratio of 2.60, with Debt / Equity ratio of 350.86%
Current Ratio2.60
Quick Ratio2.60
Debt to Market Cap0.21
Net Debt to EBITDA0.75
Interest Coverage Ratio-91.12

Taxes

In the past 12 months, Innate Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Innate Pharma EV to EBITDA ratio is -2.32, with an EV/FCF ratio of -14.91.
EV to Sales8.61
EV to EBITDA-2.32
EV to Free Cash Flow-14.91
EV to Operating Cash Flow-15.75

Balance Sheet

Innate Pharma has $80.77M in cash and marketable securities with €31.00M in debt, giving a net cash position of -$49.77M billion.
Cash & Marketable Securities$80.77M
Total Debt€31.00M
Net Cash-$49.77M
Net Cash Per Share-$0.54
Tangible Book Value Per Share$0.11

Margins

Gross margin is -100.34%, with operating margin of -408.64%, and net profit margin of -391.97%.
Gross Margin-100.34%
Operating Margin-408.64%
Pretax Margin-391.97%
Net Profit Margin-391.97%
EBITDA Margin-371.69%
EBIT Margin-387.49%

Analyst Forecast

The average price target for Innate Pharma is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.00
Price Target Upside441.87% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast-75.67%
EPS Growth Forecast-552.37%

Scores

Smart Score4
AI Score47
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis